<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3010234406
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Antopaz
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ANFARM HELLAS S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ANFARM HELLAS S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3336]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Advanced Pharmaceutical Industries
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Advanced Pharmaceutical Industries
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Antopaz 40mg Powder for Solution for Injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of 12ml of solution contains pantoprazole sodium sesquihydrate equivalent to 40 mg
pantoprazole
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clear type I glass vials 12 ml containing a white to almost white dry substance.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Reflux oesophagitis.</li><li>Gastric and duodenal ulcer.</li><li>Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicine should be administered by a healthcare professional and under appropriate medical<br />supervision.<br />Intravenous administration of Pantoprazole is recommended only if oral administration is not<br />appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral<br />therapy is possible, treatment with Pantoprazole 40 mg powder for solution for injection/infusion<br />should be discontinued and 40 mg pantoprazole p.o. should be administered instead.<br />Posology<br />Gastric and duodenal ulcer, reflux oesophagitis<br />The recommended intravenous dose is one vial of Pantoprazole (40 mg pantoprazole) per day.<br />Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions<br />For the long-term management of Zollinger-Ellison-Syndrome and other pathological<br />hypersecretory conditions patients should start their treatment with a daily dose of 80 mg</p><p>Pantoprazole. Thereafter, the dose can be titrated up or down as needed using measurements of<br />gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given<br />twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not<br />be applied longer than required for adequate acid control.<br />In case a rapid acid control is required, a starting dose of 2 x 80 mg Pantoprazole is sufficient to<br />manage a decrease of acid output into the target range (&lt;10 mEq/h) within one hour in the majority<br />of patients.<br />Special populations<br />Patients with hepatic impairment<br />A daily dose of 20 mg pantoprazole (half a vial of 40 mg pantoprazole) should not be exceeded in<br />patients with severe liver impairment (see section 4.4).<br />Patients with renal impairment<br />No dose adjustment is necessary in patients with impaired renal function.<br />Elderly population<br />No dose adjustment is necessary in elderly patients.<br />Paediatric patients<br />The experience in children is limited. Therefore, Pantoprazole is not recommended for use in<br />patients below 18 years of age until further data become available.<br />Method of administration<br />A ready-to-use solution is prepared in 10 ml of sodium chloride 9 mg/ml (0.9 %) solution for<br />injection. For instructions for preparation see section 6.6. The prepared solution may be<br />administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml<br />(0.9 %) solution for injection or glucose 50 mg/ml (5 %) solution for injection.<br />The solution obtained should be administered within 12 hours (see section 6.3).<br />The medicinal product should be administered intravenously over 2 - 15 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles, or to any of the excipients
listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastric malignancy<br />Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may<br />delay diagnosis. In the presence of any alarm symptom (e. g. significant unintentional weight loss,<br />recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is<br />suspected or present, malignancy should be excluded.<br />Further investigation is to be considered if symptoms persist despite adequate treatment.<br />Hepatic Impairment<br />In patients with severe liver impairment, the liver enzymes should be monitored during therapy. In<br />the case of a rise of the liver enzymes, the treatment should be discontinued (see section 4.2).<br />Co-administration with HIV protease inhibitors<br />Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which<br />absorption is dependent on acidic intragastric pH such as atazanavir, due to significant reduction in<br />their bioavailability (see section 4.5).<br />Combination therapy<br />In the case of combination therapy, the summaries of product characteristics of the respective<br />medicinal products should be observed.<br />Influence on vitamin B12 absorption<br />In patients with Zollinger-Ellison syndrome and other pathological hyper secretory conditions<br />requiring long-term treatment, pantoprazole, as all acid-blocking medicines, may reduce the<br />absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be<br />considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption<br />on long-term therapy or if respective clinical symptoms are observed.<br />Gastrointestinal infections caused by bacteria</p><p>Pantoprazole, like all proton pump inhibitors (PPIs), might be expected to increase the counts of<br />bacteria normally present in the upper gastrointestinal tract. Treatment with Pantoprazole may lead<br />to a slightly increased risk of gastrointestinal infections caused by bacteria such as Salmonella and<br />Campylobacter.<br />Sodium<br />This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. is essentially<br />&#39;sodium-free&#39;.<br />Hypomagnesaemia<br />Severe hypomagnesaemia has been reported in patients treated with PPIs like Pantoprazole for at<br />least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such<br />as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they<br />may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved<br />after magnesium replacement and discontinuation of the PPI.<br />For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may<br />cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring<br />magnesium levels before starting PPI treatment and periodically during treatment.<br />Bone fractures<br />Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may<br />modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in<br />presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors<br />may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk<br />factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines<br />and they should have an adequate intake of vitamin D and calcium.<br />Subacute cutaneous lupus erythematosus (SCLE)<br />Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur,<br />especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should<br />seek medical help promptly and the health care professional should consider stopping Pantoprazole.<br />SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with<br />other proton pump inhibitors.</p><p>Interference with laboratory tests<br />Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine<br />tumours. To avoid this interference, Pantoprazole treatment should be stopped for at least 5 days<br />before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference<br />range after initial measurement, measurements should be repeated 14 days after cessation of proton<br />pump inhibitor treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicinal products with pH dependent absorption pharmacokinetics<br />Because of profound and long-lasting inhibition of gastric acid secretion, pantoprazole may reduce<br />the absorption of other medicinal products where gastric pH is an important determinant of oral<br />bioavailability, e.g some azole antifungals such as ketoconazole, itraconazole, posaconazole and<br />other medicine as erlotinib.<br />HIV protease inhibitors<br />Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which<br />absorption is dependent on acidic intragastric pH such as atazanavir due to significant reduction in<br />their bioavailability (see section 4.4).<br />If the combination of HIV protease inhibitors with a proton pump inhibitor is judged unavoidable,<br />close clinical monitoring (e.g. virus load) is recommended. A pantoprazole dose of 20 mg per day<br />should not be exceeded. Dosage of the HIV protease inhibitor may need to be adjusted.<br />Coumarin anticoagulants (phenprocoumon or warfarin)<br />Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the<br />pharmacokinetics of warfarin, phenoprocoumon or INR. However, there have been reports of<br />increased INR and prothrombin time in patients receiving PPIs and warfarin or phenoprocoumon<br />concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding, and even<br />death. Patients treated with pantoprazole and warfarin or phenprocoumon may need to be monitored<br />for increase in INR and prothrombin time.<br />Methotrexate</p><p>Concomitant use of high dose of methotrexate (e.g. 300 mg) and proton pump inhibitors has been<br />reported to increase methotrexate levels in some patients. Therefore in settings where high-dose<br />methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole<br />may need to be considered.<br />Other interaction studies<br />Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The<br />main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include<br />oxidation by CYP3A4.<br />Interaction studies with drugs also metabolized with these pathways, like carbamazepine, diazepam,<br />glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and ethinyl oestradiol<br />did not reveal clinically significant interactions.<br />Results from a range of interaction studies demonstrate that pantoprazole does not effect the<br />metabolism of active substances metabolised by CYP1A2 (such as caffeine, theophylline), CYP2C9<br />(such as piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as<br />ethanol) or does not interfere with p-glycoprotein related absorption of digoxin.<br />There were no interactions with concomitantly administered antacids.<br />Interaction studies have also been performed administering pantoprazole concomitantly with the<br />respective antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically relevant<br />interactions were found.<br />Medicinal products that inhibit or induce CYP2C19<br />Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole.<br />A dose reduction may be considered for patients treated long-term with high doses of pantoprazole,<br />or those with hepatic impairment.<br />Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s wort<br />(Hypericum perforatum) may reduce the plasma concentrations of PPIs that are metabolized through<br />these enzyme systems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate<br />no malformative or feto/ neonatal toxicity of pantoprazole 40 mg powder for solution for injection.<br />Animal studies have shown reproductive toxicity (see section 5.3).<br />As a precautionary measure, it is preferable to avoid the use of pantoprazole during pregnancy.<br />Breast-feeding<br />Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient<br />information on the excretion of pantoprazole in human milk but excretion into human milk has been<br />reported. A risk to the newborns/infants cannot be excluded. Therefore a decision on whether to<br />discontinue breast-feeding or to discontinue/abstain from pantoprazole therapy should take into<br />account the benefit of breast-feeding for the child, and the benefit of pantoprazole therapy for the<br />woman.<br />Fertility<br />There was no evidence of impaired fertility following the administration of pantoprazole in animal<br />studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Approximately 5 % of patients can be expected to experience adverse drug reactions (ADRs). The most commonly reported ADRs is injection site thrombophlebitis. Diarrhoea and headache occurred in approximately 1 % of patients.<br />The table below lists adverse reactions reported with pantoprazole, ranked under the following<br />frequency classification:<br />Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>For all adverse reactions reported from post-marketing experience, it is not possible to apply any<br />Adverse Reaction frequency and therefore they are mentioned with a &ldquo;not known&rdquo; frequency.<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />Table 1. Adverse reactions with pantoprazole in clinical trials and post-marketing experience</p><table border="1" cellspacing="1" cellpadding="1" style="width:844px"><tbody><tr><td style="width:212px">Frequency</td><td rowspan="2" colspan="1" style="width:111px">Common</td><td rowspan="2" colspan="1" style="width:117px">Uncommon</td><td rowspan="2" colspan="1" style="width:94px">Rare</td><td rowspan="2" colspan="1" style="width:90px">Very rare</td><td rowspan="2" colspan="1" style="width:195px">Not known</td></tr><tr><td style="width:212px">System Organ Class</td></tr><tr><td style="width:212px">Blood and Lymphatic System Disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">&nbsp;</td><td style="width:94px">Agranulocytosis</td><td style="width:90px">Thrombocytopenia;<br />Leukopenia;<br />Pancytopenia</td><td style="width:195px">&nbsp;</td></tr><tr><td style="width:212px">Immune System Disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">&nbsp;</td><td style="width:94px">Hypersensitivity<br />(including<br />anaphylactic<br />reactions and<br />anaphylactic<br />shock)</td><td style="width:90px">&nbsp;</td><td style="width:195px">&nbsp;</td></tr><tr><td style="width:212px">Metabolism and nutrition disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">&nbsp;</td><td style="width:94px">Hyperlipidaemias<br />and lipid<br />increases<br />(triglycerides,<br />cholesterol);<br />Weight changes</td><td style="width:90px">&nbsp;</td><td style="width:195px">Hyponatraemia;<br />Hypomagnesaemia<br />(see section 4.4);<br />Hypocalcaemia(1);<br />Hupokalaemia</td></tr><tr><td style="width:212px">Psychiatric disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">Sleep disorder</td><td style="width:94px">Depression (and<br />all aggravations)</td><td style="width:90px">Disorientation (and<br />all aggravations)</td><td style="width:195px">Hallucination;<br />Confusion<br />(especially in predisposed<br />patients, as well as the<br />aggravation of thhese symptoms in&nbsp;case of preexistence)</td></tr><tr><td style="width:212px">Nervous system disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">Headache;<br />Dizziness</td><td style="width:94px">Taste disorders</td><td style="width:90px">&nbsp;</td><td style="width:195px">Parasthesia</td></tr><tr><td style="width:212px">Eye disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">&nbsp;</td><td style="width:94px">Disturbances in<br />vision / blurred<br />vision</td><td style="width:90px">&nbsp;</td><td style="width:195px">&nbsp;</td></tr><tr><td style="width:212px">Gastrointestinal disorders</td><td style="width:111px">Fundic gland polyps (benign)</td><td style="width:117px">Diarrhoea;<br />Nausea / vomiting;<br />Abdominal distension and<br />bloating;<br />Constipation;<br />Dry mouth;<br />Abdominal<br />pain and<br />discomfort</td><td style="width:94px">&nbsp;</td><td style="width:90px">&nbsp;</td><td style="width:195px">Microscopic<br />colitis</td></tr><tr><td style="width:212px">Hepatobiliary disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">Liver enzymes<br />increased<br />(transaminases,<br />&gamma;-GT)</td><td style="width:94px">Bilirubin<br />increased</td><td style="width:90px">&nbsp;</td><td style="width:195px">Hepatocellular<br />injury; Jaundice;<br />Hepatocellular<br />failure</td></tr><tr><td style="width:212px">Skin and<br />subcutaneous<br />tissue disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">Rash /<br />exanthema /<br />eruption;<br />Pruritus</td><td style="width:94px">Urticaria;<br />Angioedema</td><td style="width:90px">&nbsp;</td><td style="width:195px">Stevens-John-son<br />syndrome; Lyell<br />syndrome;<br />Erythema<br />multiform; Photosensitivity;<br />Subacute<br />cutaneous lupus&nbsp;erythematosus (see section 4.4).</td></tr><tr><td style="width:212px">Musculoskeletal and connective<br />tissue disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">Fracture of the<br />hip, wrist or spine (see section 4.4)</td><td style="width:94px">Arthralgia;<br />Myalgia</td><td style="width:90px">&nbsp;</td><td style="width:195px">Muscle spasm <sup>(2)</sup></td></tr><tr><td style="width:212px">Renal and urinary disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">&nbsp;</td><td style="width:94px">&nbsp;</td><td style="width:90px">&nbsp;</td><td style="width:195px">Interstitial nephritis (with<br />possible progression to renal failure)</td></tr><tr><td style="width:212px">Reproductive system and breast disorders</td><td style="width:111px">&nbsp;</td><td style="width:117px">&nbsp;</td><td style="width:94px">Gynaecomastia</td><td style="width:90px">&nbsp;</td><td style="width:195px">&nbsp;</td></tr><tr><td style="width:212px">General disorders and administration<br />site conditions</td><td style="width:111px">Injection site<br />thrombophlebitis</td><td style="width:117px">Asthenia, fatigue and malaise</td><td style="width:94px">Body<br />temperature<br />increased;<br />Oedema peripheral</td><td style="width:90px">&nbsp;</td><td style="width:195px">&nbsp;</td></tr></tbody></table><p>(1) Hypocalcemia in association with hypomagnesemia<br />(2) Muscle spasm as a consequence of electrolyte disturbance.</p><p>Reporting of suspected adverse reactions<br />To report any side effect(s):<br />&bull;Saudi Arabia:<br />National Pharmacovigilance Center (NPC)<br />Fax: +966-11-2057662<br />Toll free: 800249000<br />Vigilance and Crisis Management Executive Directorate<br />Tel: +966-11-20382222 Ext. 2317-2334-2340 &ndash;2353 &ndash;2354- 2356<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known symptoms of overdose in man.<br />Systemic exposure with up to 240 mg administered intravenously over 2 minutes were well<br />tolerated.<br />As pantoprazole is extensively protein bound, it is not readily dialysable.<br />In the case of an overdose with clinical signs of intoxication, apart from symptomatic and supportive<br />treatment, no specific therapeutic recommendations can be made.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid related disorders, Drugs for peptic ulcer and gastrooesophageal<br />reflux disease (GORD). Proton pump inhibitors, ATC code: A02BC02<br />Mechanism of action<br />Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the<br />stomach by specific blockade of the proton pumps of the parietal cells.<br />Pharmacodynamic effects</p><p>Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it<br />inhibits the H+, K+-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in<br />the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion.<br />In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump<br />inhibitors and H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach<br />and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is<br />reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit<br />hydrochloric acid secretion independently of stimulation by other substances (acetylcholine,<br />histamine, gastrin). The effect is the same whether the product is given orally or intravenously.<br />Pharmacodynamic effects<br />The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not<br />exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases.<br />An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate<br />increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of<br />cases during long-term treatment (simple to adenomatoid hyperplasia). However, according to the<br />studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric<br />carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.<br />An influence of a long term treatment with pantoprazole exceeding one year cannot be completely<br />ruled out on endocrine parameters of the thyroid according to results in animal studies.<br />During treatment with antisecretory medicinal products, serum gastrin increases in response to the<br />decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA<br />level may interfere with investigations for neuroendocrine tumours.<br />Available published evidence suggests that proton pump inhibitors should be discontinued between<br />5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be<br />spuriously elevated following PPI treatment to return to reference range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General pharmacokinetics<br />Pharmacokinetics does not vary after single or repeated administration. In the dose range of 10 to 80<br />mg, the plasma kinetics of pantoprazole is linear after both oral and intravenous administration.<br />Distribution<br />Pantoprazole&#39;s serum protein binding is about 98 %. Volume of distribution is about 0.15 l/kg<br />Biotransformation<br />The substance is almost exclusively metabolized in the liver. The main metabolic pathway is<br />demethylation by CYP2C19 with subsequent sulphate conjugation, other metabolic pathway<br />includes oxidation by CYP3A4.<br />Elimination<br />Terminal half-life is about 1 hour and clearance is about 0.1 l/h/kg. There were a few cases of<br />subjects with delayed elimination. Because of the specific binding of pantoprazole to the proton<br />pumps of the parietal cell the elimination half-life does not correlate with the much longer duration<br />of action (inhibition of acid secretion).<br />Renal elimination represents the major route of excretion (about 80 %) for the metabolites of<br />pantoprazole, the rest is excreted with the faeces. The main metabolite in both the serum and urine is<br />desmethylpantoprazole which is conjugated with sulphate. The half-life of the main metabolite<br />(about 1.5 hours) is not much longer than that of pantoprazole.<br />Special populations<br />Poor metabolisers<br />Approximately 3 % of the European population lack a functional CYP2C19 enzyme and are called<br />poor metabolisers. In these individuals the metabolism of pantoprazole is probably mainly catalysed<br />by CYP3A4. After a single-dose administration of 40 mg pantoprazole, the mean area under the<br />plasma concentration-time curve was approximately 6 times higher in poor metabolisers than in<br />subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma</p><p>concentrations were increased by about 60 %. These findings have no implications for the posology<br />of pantoprazole.<br />Renal impairment<br />No dose reduction is recommended when pantoprazole is administered to patients with impaired<br />renal function (incl. dialysis patients). As with healthy subjects, pantoprazole&#39;s half-life is short.<br />Only very small amounts of pantoprazole are dialyzed. Although the main metabolite has a<br />moderately delayed half-life (2 - 3 h), excretion is still rapid and thus accumulation does not occur.<br />Hepatic impairment<br />Although for patients with liver cirrhosis (classes A and B according to Child) the half-life values<br />increased to between 7 and 9 h and the AUC values increased by a factor of 5 - 7, the maximum<br />serum concentration only increased slightly by a factor of 1.5 compared with healthy subjects.<br />Older people<br />A slight increase in AUC and Cmax in elderly volunteers compared with younger counterparts is<br />also not clinically relevant.<br />Pediatric population<br />Following administration of single intravenous doses of 0.8 or 1.6 mg/kg pantoprazole to children<br />aged 2 - 16 years there was no significant association between pantoprazole clearance and age or<br />weight. AUC and volume of distribution were in accordance with data from adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard to humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity and genotoxicity.<br />In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition,<br />squamous cell papillomas were found in the forestomach of rats. The mechanism leading to the<br />formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and<br />allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels<br />occurring in the rat during chronic high-dose treatment. In the two-year rodent studies an increased</p><p>number of liver tumors was observed in rats and in female mice and was interpreted as being due to<br />pantoprazole&#39;s high metabolic rate in the liver.<br />A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving<br />the highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the<br />pantoprazole-induced changes in the breakdown of thyroxine in the rat liver. As the therapeutic<br />dose in man is low, no harmful effects on the thyroid glands are expected.<br />In animal reproduction studies, signs of slight fetotoxicity were observed at doses above 5 mg/kg.<br />Investigations revealed no evidence of impaired fertility or teratogenic effects.<br />Penetration of the placenta was investigated in the rat and was found to increase with advanced<br />gestation. As a result, concentration of pantoprazole in the foetus is increased shortly before birth.<br />Data to evaluate a potential effect on the environment is currently limited (see item 6.6 &ndash; disposal<br />of pantoprazole).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in<br />section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Momths
The reconstituted solution of 40 mg/10 ml is stable for a period of 12 hours of initial puncture of
stopper Chemical and physical in-use stability has been demonstrated for 12 hours at 25°C after
dilution with sodium chloride 9mg/ml (0.9%) solution and with glucose 50 mg/ml (5%) solution.
The diluted solutions with sodium chloride 9 mg/ml (0,9%) solution and with dextrose 50 mg/ml
(5%) solution atconcentrations of 80 and 160mg doses should be administered within the infusion
time 15 minutes.
From a microbiological point of view, the prepared solution should be used immediately. If
not used immediately, in-usestorage times and conditions prior to use are the responsibility of
the user.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.<br />For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I clear glass vial of 12ml sealed with dark grey chlorobutyl rubber stopper complying with<br />current Eur. Ph. and an aluminium cap with plastic flip-off seal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A ready-to-use solution is prepared by injecting 10 ml of sodium chloride 9 mg/ml (0.9 %) solution<br />for injection into the vial containing the powder. The appearance of the product after reconstitution<br />is a clear brownish solution. Do not use if any particles are present in the reconstituted solution.<br />This solution may be administered directly or may be administered after mixing it with 100 ml<br />sodium chloride 9 mg/ml (0.9 %) solution for injection or glucose 50 mg/ml (5 %) solution for<br />injection.<br />The reconstituted solution of 40 mg/10 ml is stable for a period of 12 hours of initial puncture of<br />stopper.<br />Chemical and physical in-use stability has been demonstrated for 12 hours at 25&deg;C after dilution<br />with sodium chloride 9 mg/ml (0.9%) solution and with glucose 50 mg/ml (5%) solution.<br />The diluted solutions with sodium chloride 9 mg/ml (0,9%) solution and with dextrose 50 mg/ml<br />(5%) solution at concentrations of 80 and 160mg doses are stable during the infusion time of 15<br />minutes.<br />From a microbiological point of view, the product should be used immediately (see section 6.3).<br />Pantoprazole should not be prepared or mixed with solvents other than those stated.<br />The medicine should be administered intravenously over 2-15 minutes.<br />The contents of the vial are for single use only. Any product that has remained in the container<br />should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Advanced Pharmaceutical Industries Ltd.
Prince Sultan Street, Almurjanah Building
P.O.Box, 23435-2086, Jeddah, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26-01-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>